Case Study Analysis of Bipolar Disorder (Annotated Bibliography Sample)

SN003: Assessment of Specialty Clinical Practice Erica Allen Program Name or Degree Name (e.g., Master of Science in Nursing), Walden University Title of Course Instructor Name August 25, 2025 Case Study Analysis of Bipolar Disorder – Nursing Care and Safety Considerations Bipolar disorder is one of the most challenging psychiatric illnesses managed in clinical practice, marked by alternating episodes of mania, hypomania, and depression. Its recurrent and chronic nature often impairs occupational, social, and interpersonal functioning, contributing significantly to disability worldwide. In the United States, the condition affects nearly three percent of adults annually, with onset commonly occurring in late adolescence or early adulthood. Although pharmacological treatments such as lithium, valproate, and atypical antipsychotics are effective in controlling mood episodes, adherence and long-term stabilization remain problematic. Moreover, bipolar disorder carries one of the highest risks of suicide among mental health disorders, underscoring the need for vigilant monitoring and comprehensive nursing care. The management of bipolar disorder requires advanced clinical reasoning and interprofessional collaboration, as well as a deep understanding of pathophysiology, diagnostic processes, and evidence-based interventions. Nurses in advanced practice roles are uniquely positioned to integrate pharmacological knowledge, patient education, and safety strategies into holistic care. This paper presents a comprehensive case study analysis of a patient with bipolar I disorder. It describes the patient’s history and diagnosis, analyze the pathophysiology of the condition, discusses pharmacological management, and outline diagnostic and treatment planning. It also presents an annotated bibliography of peer-reviewed literature relevant to the case, develop a detailed care plan, and address quality and safety considerations. Part 1: Patient and Diagnosis The patient, here referred to as Mr. Alex for confidentiality, is a 32-year-old African American male presenting to a community psychiatric clinic following a two-week escalation of manic symptoms. He was accompanied by his spouse, who reported that he had been sleeping less than three hours nightly, spending excessively on nonessential items, and demonstrating erratic behavior at work. Mr. Alex’s speech during assessment was pressured and tangential, with evidence of flight of ideas and distractibility. He described feeling “unstoppable” and reported an increase in energy that he described as “superhuman.” Despite his elevated mood, his spouse expressed concern about irritability, volatility, and occasional verbal aggression. The patient has a history of bipolar I disorder, diagnosed at age 25 following a hospitalization for mania. His treatment regimen has included lithium carbonate for long-term mood stabilization, but recent lapses in adherence were noted. He also carries a diagnosis of generalized anxiety disorder and hypertension, for which he is prescribed lisinopril. He denied illicit drug use, and urine toxicology screening was negative. Family history revealed a maternal uncle with bipolar disorder and a father with alcohol use disorder. Mr. Alex acknowledged having suicidal ideation during prior depressive episodes but denied current intent. On mental status examination, he exhibited grandiosity, euphoric mood, and impaired insight into his illness. His vital signs were stable, and physical examination revealed no acute abnormalities. Differential diagnoses considered included schizoaffective disorder, bipolar type, which was ruled out as his psychotic-like features were exclusively mood-congruent and episodic. Major depressive disorder with psychotic features was excluded due to his documented manic episodes. Substance-induced mood disorder was ruled out after toxicology screens confirmed the absence of drugs or alcohol. The final diagnosis confirmed bipolar I disorder, current episode manic, with comorbid generalized anxiety disorder. The pathophysiology of bipolar disorder is multifactorial, involving genetic, neurochemical, and neurocircuitry abnormalities. At the cellular level, dysregulation of neurotransmitters, including dopamine, serotonin, and norepinephrine, contributes to mood fluctuations. Elevated dopaminergic activity has been associated with manic states, while reduced serotonergic transmission contributes to depressive episodes. In addition, alterations in glutamate signaling and calcium channel function create neuronal hyperexcitability. Emerging evidence suggests mitochondrial dysfunction and oxidative stress also play significant roles, impairing neuronal energy metabolism. These biological abnormalities translate into the clinical manifestations observed in bipolar disorder, including mood lability, psychomotor agitation, and cognitive disruptions. Functional imaging studies reveal abnormal connectivity between the prefrontal cortex and limbic regions, explaining the impaired regulation of mood and impulsivity commonly seen in patients such as Mr. Alex. Pharmacological management in bipolar disorder is foundational, with lithium carbonate and valproic acid among the most widely prescribed agents. Lithium’s mechanism of action involves modulation of second messenger systems, inhibition of inositol monophosphatase, and regulation of glycogen synthase kinase-3β. Clinically, lithium stabilizes mood, reduces recurrence of manic and depressive episodes, and has demonstrated anti-suicidal properties. However, it requires close monitoring, as adverse effects include tremors, polyuria, hypothyroidism, nephrogenic diabetes insipidus, and potentially life-threatening toxicity at serum levels exceeding 1.5 mEq/L. For Mr. Alex, individualized considerations include his history of nonadherence and concurrent use of lisinopril, which could impair renal clearance of lithium. Valproic acid, another first-line agent, exerts its effects through enhanced gamma-aminobutyric acid (GABA) neurotransmission, sodium channel inhibition, and modulation of glutamate activity. It is particularly effective in acute mania and mixed states. Adverse effects include hepatotoxicity, pancreatitis, sedation, and weight gain. Mr. Alex’s care plan must therefore incorporate regular liver function testing and patient education on lifestyle adjustments to counter weight gain. A structured treatment plan was established. Diagnostic confirmation was supported through a Structured Clinical Interview for DSM-5 (SCID-5), ensuring accuracy and ruling out comorbid disorders. Laboratory studies included serum lithium levels to maintain therapeutic concentrations, renal function tests to monitor for nephrotoxicity, and thyroid function tests to detect lithium-induced hypothyroidism. Short-term nursing goals included stabilizing Mr. Alex’s sleep to at least six hours nightly within two weeks and ensuring his ability to verbalize understanding of lithium’s side effects and monitoring requirements within one week. The long-term nursing goal centered on sustained medication adherence, relapse prevention, and functional recovery over six months. Part 2: Annotated Bibliography Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572. https://doi.org/10.1016/S0140-6736(15)00241-X. This article provides a comprehensive overview of bipolar disorder, including epidemiology, risk factors, clinical presentation, and treatment modalities. The authors emphasize the chronic nature of the condition and the importance of both pharmacological and psychosocial interventions. They highlight lithium’s role as the gold standard for mood stabilization while acknowledging adherence challenges. The review also addresses suicide risk and comorbidities commonly seen in patients. This article is highly relevant to Mr. Alex’s case as it contextualizes his clinical presentation within the broader literature. The findings are applicable in practice by guiding the integration of medication management with psychoeducation and relapse prevention strategies. Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press. Stahl’s text outlines the neurobiological basis of psychiatric disorders and the pharmacodynamics of psychotropic drugs. The discussion on lithium highlights its cellular actions, including modulation of second messenger systems and neuroprotective effects. The text also covers the adverse effects and monitoring requirements associated with lithium therapy. This source is directly relevant to the pharmacological management section of the case study. Its application lies in enhancing the clinician’s ability to explain drug mechanisms to patients in accessible terms, thereby improving adherence and informed decision-making. Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. The Lancet, 381(9878), 1672–1682. Geddes and Miklowitz review both pharmacological and psychosocial treatments for bipolar disorder. They emphasize lithium’s superiority in long-term relapse prevention and the benefits of adjunctive interventions such as family therapy. The article underscores the necessity of combining medication with psychoeducation to improve outcomes. This work is relevant as it directly addresses the integration of nursing education into care planning for Mr. Alex. The application of its findings supports the development of a comprehensive treatment plan combining pharmacotherapy with structured family involvement. American Psychiatric Association. (2024). The American Psychiatric Association practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Pub. This guideline synthesizes the best available evidence into practical recommendations for bipolar disorder managemen...